Latest news and press releases about Nexalin Technology, Inc. (NXL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia.
Price
| Price | $4.92 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.28 |
| EV / EBITDA | -0.30 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -278.25% |
| Return on Invested Capital | -600.62% |
| Return on Assets | -299.21% |
| Gross Margin | -148.42% |
| Operating Margin | -4202.54% |
| Net Margin | -4139.38% |
Related companies: CLGN · ENLV · HBIO · IINN · MODD · NRXS · RBOT
Explore sector: Healthcare · Medical - Devices
More sections of NXL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks